Latest for Primary Hyperoxaluria
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Primary Hyperoxaluria
As kidney function declines, the kidneys become unable to clear the excess oxalate, leading to systemic oxalosis where calcium oxalate deposits accumulate in bones, blood vessels, skin, retina, heart, and other organs. Without treatment, PH1 typically progresses to end-stage kidney disease, often requiring combined liver-kidney transplantation.
Keep reading about Primary Hyperoxaluria
Alnylam's OXLUMO (lumasiran), an RNAi therapy that silences the HAO1 gene to reduce oxalate production, was FDA-approved in 2020 and has dramatically changed the treatment paradigm. Lumasiran reduces urinary oxalate by approximately 65% and can potentially prevent kidney failure when started early. Conservative measures including high fluid intake and citrate supplementation remain important adjuncts.
What are the symptoms of Primary Hyperoxaluria?
These are common symptoms of Primary Hyperoxaluria, and how strong they are varies from person to person.
- Recurrent kidney stones, often starting in childhood
- Blood in the urine
- Severe abdominal or flank pain from kidney stones
- Recurrent urinary tract infections
- Progressive kidney disease that may lead to kidney failure
- In advanced cases, oxalate deposits in bones, eyes, heart, and skin (systemic oxalosis)
Who gets Primary Hyperoxaluria?
Can present from infancy through adulthood, though most cases of PH1 are diagnosed in childhood or adolescence. Affects males and females equally. Autosomal recessive inheritance. More common in certain populations in the Middle East and North Africa. Estimated that up to 50% of cases remain undiagnosed.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Primary Hyperoxaluria?
There are currently 2 FDA-approved medications for Primary Hyperoxaluria.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Primary Hyperoxaluria treatment
Charity funds and drugmaker programs for Primary Hyperoxaluria, checked at the source.
- From a charity · HealthWell FoundationHyperoxaluria fundOpen
Pays for: Copays, premiums or other treatment costs.
- From a charity · The Assistance FundPrimary Hyperoxaluria fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and fund for Primary Hyperoxaluria, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Primary Hyperoxaluria
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Primary Hyperoxaluria resources
Reputable organizations and medical references for learning more about Primary Hyperoxaluria, including disease registries, foundation resources, and clinical guidelines.